Dr. Unwin's clinical data shows a 93% success rate in normalizing blood sugar for pre-diabetics using a low-carb diet. This effectiveness drops to 73% for early-stage Type 2 diabetics and just 50% after five years, underscoring the urgency of early intervention.

To encourage better choices, emphasize immediate, tangible rewards over long-term, abstract goals. A Stanford study found diners chose more vegetables when labeled with delicious descriptions ("sizzling Szechuan green beans") versus health-focused ones ("nutritious green beans"). This works with the brain's value system, which prioritizes immediate gratification.

Generic nutrition apps fail to address the needs of people with specific chronic conditions. The real HealthTech opportunity is in building verticalized AI platforms that act as a central 'project manager' for one ailment, like GERD or migraines, integrating data and providing targeted advice.

The Tempo app moves beyond typical health dashboards by creating actionable 'protocols' to improve user compliance. The insight is that users don't just need more data; they need a system that helps them consistently perform health-improving behaviors, which is the core challenge in wellness.

Dr. Unwin's career pivoted after a patient revealed she normalized her blood sugar by cutting carbs—a method she learned from a 40,000-strong online community. This highlights the power of patient-led research and community knowledge in healthcare.

Research shows that while GLP-1 drug users eat less, they will pay more for high-quality ingredients. This creates a strategic opportunity for restaurants to increase profit margins by offering smaller, premium-priced dishes, tapping into the retail psychology that smaller items can carry a higher proportional markup.

Generic advice like "diet and exercise" is ineffective for cancer patients. Clinicians should adopt a pharmaceutical model, prescribing specific types and "doses" of diet and exercise based on a patient's unique metabolic profile, treatment, and clinical goals, rather than handing out a generic brochure.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

In a randomized controlled trial for stage 4 metastatic pancreatic cancer, adding Virta Health's nutritional therapy to a three-drug chemo regimen resulted in a ~35% life extension. This suggests improving metabolic health can significantly impact outcomes even in aggressive cancers.